Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus.

CONCLUSIONS: Our findings demonstrate that MCC cells can be targeted by MCV Tag-specific TCRs. Although recent findings suggest that approximately half of MCC patients benefit from PD1 pathway blockade, additional patients may benefit if their endogenous T cell response can be augmented by infusion of transgenic MCV-specific T cells such as those described here.
PMID: 29669806 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 18, 2018 Category: Cancer & Oncology Authors: Gavvovidis I, Leisegang M, Willimsky G, Miller NJ, Nghiem P, Blankenstein T Tags: Clin Cancer Res Source Type: research